Skip to main content

Table 1 Baseline characteristics of included patients

From: NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner

Variables

All patients (n = 245)

Low NCSTN (n = 107)

High NCSTN (n = 138)

P value

Patient factors/Laboratory parameters

Age [year, mean (SD)]

51.6 (12.4)

51.5 (12.4)

51.8 (12.4)

0.825

Male gender, n (%)

201 (82.0)

83 (77.6)

118 (85.5)

0.132

HBsAg, [positive, n (%)]

210 (85.7)

95 (88.8)

115 (83.3)

0.228

AFP ≥ 400, n (%)

93 (38.0)

32 (29.9)

61 (44.2)

0.022

Ascites, n (%)

30 (12.2)

12 (11.2)

18 (13.0)

0.665

Histological and gross features of tumors

Tumor size, [cm, mean (SD)]

5.7 (3.3)

4.3 (3.2)

6.3 (3.3)

< 0.001

Solitary tumor, n (%)

204 (83.3)

92 (86.0)

112 (81.1)

0.332

Tumor differentiation

   

0.027

Well/Moderate

143 (58.4)

69 (64.5)

74 (53.6)

 

Poor

102 (41.6)

38 (35.5)

64 (49.5)

 

Macrovascular invasion, n (%)

9 (3.7)

4 (3.7)

5 (3.6)

0.962

Microvascular invasion, n (%)

80 (32.7)

32 (29.9)

48 (34.8)

0.420

Cirrhosis, n (%)

153 (62.4)

66 (61.7)

87 (63.0)

0.827

TNM stage, n (%)

   

0.060

I- II

186 (75.9)

86 (80.4)

100 (72.5)

 

III

59 (24.1)

21 (19.6)

38 (27.5)

 

BCLC stage

   

0.493

A

198 (80.8)

83 (77.6)

115 (83.3))

 

B

36 (14.7)

19 (17.8)

18 (13.0)

 

C

10 (4.1)

5 (4.7)

5 (3.6)

 

Prognostic outcome

Overall survival, months, mean (95% CI)

31.5 (29.5, 33.6)

36.0 (32.7, 39.3)

28.1 (25.6, 30.6)

 
  1. TNM Tumor-node-metastasis, SD Standard deviation, CI Confidence interval